Puma Biotechnology, Inc. (NASDAQ: PBYI) went up by 3.91% from its latest closing price when compared to the 1-year high value of $65.45, while PBYI stocks collected -42.38% of loss with the last five trading sessions.
Puma Biotechnology, Inc. (NASDAQ: PBYI) Worth an Investment?
Puma Biotechnology, Inc. (NASDAQ: PBYI) The 36 Months beta value for PBYI stocks is at 0.62, while 0 of the analysts out of 10 who provided ratings for Puma Biotechnology, Inc. stocks as a “buy” while 0 as overweight, 7 rated it as hold and 2 as sell. The average price we get from analysts is $24.78 which is $24.45 above current price. PBYI currently has a short float of 13.19% and public float of 32.96M with average trading volume of 1.18M shares.
PBYI Market Performance
PBYI stocks went down by -42.38% for the week, with the monthly drop of -48.86% and a quarterly performance of -34.93%, while its annual performance rate touched -66.98%. The simple moving average for the period of the last 20 days is -43.57% for PBYI stocks with the simple moving average of -48.62% for the last 200 days.
Analysts’ Opinion on Puma Biotechnology, Inc. (NASDAQ: PBYI)
Many brokerage firms have already submitted their reports for PBYI stocks, with Citigroup repeating the rating for PBYI shares by setting it to “Neutral”. The predicted price for PBYI socks in the upcoming period according to Citigroup is $24 based on the research report published on May 10, 2019.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see PBYI stock at the price of $20, previously predicting the value of $57. The rating they have provided for PBYI stocks is “Neutral” according to the report published on May 10, 2019.
Leerink Partners gave “Mkt Perform” rating to PBYI stocks, setting the target price at $21 in the report published on January 17, 2019.
PBYI Stocks -50.18% Far from 50 Day Moving Average
After a stumble in the market that brought PBYI to its low price for the period of the last 52 weeks, Puma Biotechnology, Inc. was unable to take a rebound, for now settling with -73.19% of loss for the given period.
The stock volatility was left at 5.46%, however, within the period of a single month, the volatility rate increased by 8.14%, while the shares sank at the distance of -48.18% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -56.21% lower at the present time.
In the course of the last 5 trading sessions, PBYI went down by -42.38%, which changed the moving average for the period of 200 days to the total of -65.45% of losses for the stock in comparison to the 20-day moving average settled at $30.28. In addition, Puma Biotechnology, Inc. saw -13.76% in overturn over the period of a single year with a tendency to cut further losses.
PBYI Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Puma Biotechnology, Inc. (PBYI), starting from BRYCE RICHARD PAUL, who sold 85 shares at the price of $32.38 back on May 02. After this action, Rushing now owns 38,924 shares of Puma Biotechnology, Inc., valued at $2,752 with the latest closing price.
AUERBACH ALAN H, the PRESIDENT AND CEO of Puma Biotechnology, Inc., sold 477 shares at the value of $32.38 during a trade that took place back on May 02, which means that AUERBACH ALAN H is holding 4,203,218 shares at the value of $15,445 based on the most recent closing price.
PBYI Stock Fundamentals
The current profitability levels are settled at -37.72 for the present operating margin and +86.21 for gross margin. The net margin for Puma Biotechnology, Inc. stands at -45.25. Total capital return value is set at -65.75, while invested capital returns managed to touch -78.88. Equity return holds the value -258.20%, with -51.20% for asset returns.
Based on Puma Biotechnology, Inc. (PBYI), the company’s capital structure generated 442.74 points for debt to equity in total, while total debt to capital is set at the value of 81.57. Total debt to assets is settled at the value of 58.62 with long-term debt to equity ratio rests at 442.74 and long-term debt to capital is 81.57.
The value for Enterprise to Sales is 2.46 with debt to enterprise value settled at 0.20. The receivables turnover for Puma Biotechnology, Inc. is 15.88 with the total asset turnover at the value of 1.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.02.